- This event has passed.
Rachel Buckley, PhD
Rachel Buckley, PhD
Rachel Buckley is an Assistant Professor of Neurology at Harvard Medical School, with a primary appointment at Massachusetts General Hospital. After initially completing her PhD in Neuropsychology at the University of Melbourne, Australia, with the Australian Imaging Biomarker and Lifestyle Study of Aging, she then moved to Boston to train in PET neuroimaging and cognitive decline under Dr. Reisa Sperling at the Harvard Aging Brain Study. Her research interests lie in sex differences in risk for Alzheimer’s disease, with a particular focus on women’s health (menopause and the X chromosome) and AD risk. She holds multiple NIH grants, including an NIH K99/R00 Pathway to Independence Award and DP2 New Innovator Award, as well as a fellowship from the Alzheimer’s Association, that seek to examine the role of menopause, sex hormones and the X chromosome to impact risk and resilience to AD in both men and women. Rachel is also the Vice-Chair of the Sex and Gender Differences in Alzheimer’s disease Professional Interest Area for the Alzheimer’s Association.
Heather M. Snyder, PhD
Heather Snyder is the VP of Medical and Scientific Relations at the Alzheimer’s Association. She oversees Association initiatives that accelerate Alzheimer’s research and provideopportunities for the global dementia community. She is responsible for overseeing the progress the Association has made in Alzheimer’s and dementia research funding. She leads the Association’s International Research Grant Program and strategic funding initiatives, through which the Association funds investigations that advance understanding of Alzheimer’s and moves the field toward solutions for the global Alzheimer’s crisis. As the world’s largest nonprofit funder of Alzheimer’s research, the Association is currently investing over $300 million in more than 920 active best-of-field projects in 45 countries.
SWHR’s Value of Diagnostics within Women’s Health series is supported by an educational sponsorship from Roche. SWHR maintains independence and editorial control over program development, content, and work products.